Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139047 · ClinicalTrials.gov registry record · Phase 4
Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin
A Phase 4 study of Skin Manifestations, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT01139047 is a Phase 4 study of Skin Manifestations that has completed, run by Galderma R&D. The registered enrollment target is 77 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01139047, a Phase 4 study of Skin Manifestations, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
Conditions Studied
Interventions
- DRUG metronidazole 1% gel
- DRUG azelaic acid 15% gel
Study Locations (1)
Colorado
- Thomas J. Stephens & Associates, Inc. - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139047
The ClinicalTrials.gov registry entry for NCT01139047 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Manifestations appearing as the primary indexed condition, and to 2 interventions - of which metronidazole 1% gel is the first listed.
NCT01139047 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01139047 about?
NCT01139047 is a clinical study titled "Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin". The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
What is the current status of trial NCT01139047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2010-06. Estimated completion is 2010-06.
What conditions does trial NCT01139047 study?
This clinical trial studies the following conditions: Skin Manifestations.
What interventions are being tested in trial NCT01139047?
The interventions under investigation include: metronidazole 1% gel (DRUG), azelaic acid 15% gel (DRUG).
Who is sponsoring clinical trial NCT01139047?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01139047 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Manifestations
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.